Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biorez, Inc.

http://biorez.com/

Latest From Biorez, Inc.

$25 Million ‘Pure Fiction’ In Natrol Price Tag Made Real

Natrol owner Aurobindo asks a bankruptcy court for an order before previous owner Plethico Pharmaceuticals agrees to pay close to the price of a phantom engineering contract Plethico claimed as a debt. Aurobindo alleged Plethico sold Natrol to prevent creditors from uncovering the sham.

Consumer India

$25 Million ‘Pure Fiction’ In Natrol Price Tag Made Real

Natrol owner Aurobindo asks a bankruptcy court for an order before previous owner Plethico Pharmaceuticals agrees to pay close to the price of a phantom engineering contract Plethico claimed as a debt. Aurobindo alleged Plethico sold Natrol to prevent creditors from uncovering the sham.

Consumer India

Aurobindo Settles Dispute With Plethico Over Natrol Fraud Charges

Last year Aurobindo acquired Plethico’s Natrol dietary supplements business in the U.S., which was divested as part of court-directed bankruptcy proceedings. A few months on, the Hyderabad-based drug maker filed a case charging the seller of perpetrating fraud. Aurobindo has now informed Indian stock exchanges that it agreed to settle the matter in return for certain cash payments and transfer of assets from Plethico.

BioPharmaceutical Asia Pacific

Supplement Space Exits: Bankruptcy Traffic Could Accelerate

Gaspari Nutrition, acquired by Allegro Nutrition, sought Chapter 11 protection after its debt load outstripped its revenue outlook. Natrol threw in the towel and filed after federal judges consolidated multiple class action claims accusing the firm of false advertising for its joint relief products.

Consumer United States
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Soft Tissue Regeneration
UsernamePublicRestriction

Register